Patent · US Active

Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use

US10828305B2 · kind B2 · utility

1Cited by

4References

17Claims

0Family size

Assignee

Shanghai Pharmaceuticals Holding Co., Ltd. · CN

Inventors

Guangxin Xia · Shanghai, CN
Di Li · Lanzhou, CN
Hongjian Zuo · Shanghai, CN
Guangsheng Wu · Nanhu, CN
Lingjun DUAN · Shanghai, CN
Jing Zhang · Wantage, US
Yu MAO · Shanghai, CN
Yanjun Liu · Shanghai, CN

Key dates

Filing date	Mar 1, 2017
Grant date	Nov 10, 2020
Priority date	—
Expiry date	Mar 1, 2037

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02P20/55
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.